Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Shoko Nishiya has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An open label, uncontrolled clinical trial of immunogenicity and safety of yellow fever vaccine in adults with chronic kidney disease as compared to immunocompetent

    by Amanda Caroline Ribeiro Sales, Camila de Melo Picone, Adriana de Souza Azevedo Soares, Sheila Maria Barbosa de Lima, Anna Nishiya, Pedro Henrique Theotonio de Mesquita Pacheco, Paula Keiko Sato, Camila Cristina Martini Rodrigues, Marta Heloisa Lopes, Amanda Nazareth Lara, et al.

  • Absence of Detectable Anti‐ HDV Antibodies Among HBsAg ‐Positive Blood Donors, HIV ‐Infected Individuals and Patients With Chronic Hepatitis B in Sao Paulo, Brazil: Evaluation Using a Rapid Lateral Flow Assay

    by Anna S. Nishiya, Cecilia S. Alencar, Michele Soares Gomes Gouvea, Suzane K. Ono, Nanci Alves Salles, Alfredo Mendrone, Gnimah Eva Gnouamozi, Shirin Nkongolo, Stephan Urban, Raymond F. Schinazi, et al.

    Hepatitis Delta Virus (HDV) infection in HBV‐infected individuals is associated with severe clinical outcomes, and screening is recommended in HBsAg‐positive patients. We used a rapid lateral flow assay (LFA) to assess anti‐HDV antibodies in Brazil, where HDV is highly endemic in the North, while data from the Southeast, particularly São Paulo, remain limited. We conducted a retrospective cross‐sectional study to assess anti‐HDV antibodies among 46 HBsAg‐positive blood donors at Fundação Pró‐Sangue/Hemocentro de São Paulo, 381 patients with chronic hepatitis B from the Central Laboratory Division of HC‐FMUSP, and 189 individuals from the Hepatology Clinic of HC‐FMUSP (101 HIV‐infected and 88 chronically HBV‐infected). Anti‐HDV antibodies were detected using a validated LFA. Positive controls ( n = 24) included samples previously confirmed by ELISA and/or PCR, predominantly infected with HDV genotypes 3 and 8. Among 443,400 blood donations, 48 (0.01%) were positive for at least two HBV markers; of these, 46 were tested for HDV, and all were anti‐HDV negative. All 381 patients undergoing HBV viral load monitoring were anti‐HDV negative, as were all 189 patients receiving hepatology care, including those with HIV coinfection or advanced liver disease. The LFA correctly identified all control samples positive for both anti‐HDV antibodies and HDV RNA. The absence of detectable anti‐HDV among diverse at‐risk populations in São Paulo is consistent with the low endemicity of HDV infection in southeastern Brazil. These findings, together with the assay's high specificity in HDV RNA‐positive controls, support its potential utility as a screening tool for HDV infection in low‐prevalence settings.

  • Open Access

    Immunogenicity and safety of yellow fever vaccine in adults with chronic kidney disease

    by Ana Marli Christovam Sartori, Amanda Caroline Ribeiro Sales, Camila Melo Picone, Adriana de Souza Azevedo, Sheila Maria Barbosa de Lima, Anna Shoko Nishiya Oshiro, Pedro H. M. Pacheco, Paula Keiko Sato, Camila Cristina Martini Rodrigues, Marta Heloisa Lopes, et al.

    Background: During a yellow fever (YF) epidemic in Brazil, vaccination campaigns targeting the entire population in the affected areas were conducted, bringing up an opportunity to prospectively evaluate YF vaccine’s immunogenicity and safety in adults with chronic kidney disease (CKD) compared to healthy adults.Methods: Open-label trial involved adults aged ≥18 years with CKD on dialysis (CKD-D) or not (CKD-ND) and healthy, who denied previous YF vaccination. All them received a YF vaccine standard dose. Adverse events (AE) were monitored within 15 days after vaccination. Neutralizing antibodies were measured by microneutralization test with 50% reduction of lysis plaques (micro-PRN50). Viremia was evaluated by RT-PCR.Results: 154 participants were included: 54 CKD-D, 41 with CKD-ND and 59 healthy. Median age was 50, 61 and 47 years, respectively. Ten days after vaccination (D10), seropositivity was significantly lower in CKD (CKD-ND, 62.3%; CKD-D, 48%) than in healthy (86.7%) and CKD participants had lower antibody geometric mean titers (GMT). On D30, GMT increased in all three groups, and seropositivity rates and GMT of CKD and healthy groups were not significantly different. On D365, most participants in the three groups persisted seropositive, with a GMT decrease in all three groups, without significant differences. On D10, viremia was detected in 28.8% of CKD-D; 32.3% of CKD-ND, and 28.9% of healthy, without significant difference between groups, but CKD participants had lower viremia. Healthy participants more frequently reported AE (66.7%) than CKD-ND (48.5%) and CKD-D (48.8%). Most common AE were headache (32.7%), myalgia (28.4%) and injection site pain (25.3%). Conclusions. CKD adults had a robust although delayed neutralizing antibody response to YF vaccine. The vaccine was well-tolerated by adults with CKD, but the sample size did not allow conclusions on vaccine-related severe AE.

  • Open Access

    Assessment of Leishmania exposure in blood donors from a non‐endemic urban area: A study in São Paulo

    by Ismael Severino de Lima, Suzete Cleusa Ferreira, Anna Shoko Nishiya, Norival Kesper, Jerenice Esdras Ferreira, Claudia Maria de Castro Gomes, Juliana Derriga, Katia Cristina Dantas, Silvia Petrossi Gallo Polato, Nanci Alves Salles, et al.

    Background and Objectives: According to the World Health Organization, more than 1 billion people are at risk of leishmaniasis in over 89 countries. Environmental changes such as deforestation, urban expansion and climate change facilitate the spread of sand fly vectors and reservoirs, increasing disease transmission. The introduction of Leishmania into non‐endemic regions may be further driven by globalization and ecotourism. Transfusion transmission, particularly of Leishmania infantum , remains a concern due to the parasite's ability to survive under blood storage conditions and its prolonged latent phase. We aimed to determine the prevalence of Leishmania spp. among blood donors in a non‐endemic region. Materials and Methods: A prospective, cross‐sectional study was conducted with 5145 blood donor samples collected from January to December 2023. Serological screening was performed using an in‐house immunoglobulin G (IgG) ELISA based on Leishmania chagasi antigen. Samples with positive or inconclusive ELISA results were further tested by real‐time PCR targeting internal transcribed spacer (ITS) and kinetoplast DNA (kDNA) regions, according to Pirmez et al. Results: Among samples tested, 2.82% (141/5145) were ELISA‐reactive. None of these were positive by PCR for ITS or kDNA. Conclusion: The absence of Leishmania DNA in ELISA‐reactive samples highlights the limitations of serological screening in low‐endemicity areas. Inflammatory physiological conditions, such as pregnancy and abortion, may contribute to non‐specific reactivity. The incorporation of molecular methods and the adoption of universal leukoreduction are recommended measures to ensure transfusion safety and avoid unnecessary donor deferrals.

  • Assessing the effect of policy change on transfusion safety in Brazil: A three‐and‐a‐half‐year study after lifting the deferral for men who have sex with men

    by Anna Nishiya, Suzete Ferreira, Cesar de Almeida‐Neto, Caio Almeida, Nanci Salles, Vanderson Rocha, Alfredo Mendrone‐Junior

    Background and Objectives: In July 2020, Brazil removed the long‐standing restrictions on blood donation by men who have sex with men (MSM) , shifting donor eligibility criteria towards individual behavioural risk assessment. We sought to establish the impact of this policy change on the safety of the blood supply. Materials and Methods: This retrospective cross‐sectional study evaluated the prevalence and incidence of human immunodeficiency virus ( HIV) , hepatitis B virus ( HBV) , hepatitis C virus ( HCV) and syphilis among blood donors at Fundação Pró‐Sangue/Hemocentro de São Paulo. Data were analysed across two periods: before ( P1 : January 2019–June 2020) and after ( P2 : July 2020–December 2023) the MSM policy change. Prevalence was assessed in first‐time donors, and incidence was calculated among repeat donors. The chi‐square testing was used for statistical comparisons ( p < 0.05). Results: A total of 560,528 donations were included in the study. There were no significant differences in the prevalence per 100,000 donations of HIV (46.3 vs. 43.5; p = 0.77), HBV (33.3 vs. 27.7; p = 0.56) or HCV (94.1 vs. 72.6; p = 0.09) markers between P1 and P2 . However, the prevalence of serological markers for syphilis increased significantly (745.7 vs. 1115.8; p < 0.0001) after the policy change. Donors with positive serological markers for syphilis in P2 were mostly younger and had higher education levels. Conclusion: Lifting the MSM deferral policy in Brazil did not increase the prevalence or incidence of HIV , HBV or HCV markers among blood donors. The observed increase in the prevalence of serological markers for syphilis likely reflects broader population trends. These findings support risk‐based donor screening as a safe and equitable approach to blood collection.

  • Open Access

    Genetic diversity in the partial sequence of the HIV-1 gag gene among people living with multidrug-resistant HIV-1 infection

    by Cecília Salete Alencar, Ester Cerdeira Sabino, Ricardo Sobhie Diaz, Alfredo Mendrone-Junior, Anna Shoko Nishiya

    The group-specific antigen (gag) plays a crucial role in the assembly, release, and maturation of HIV. This study aimed to analyze the partial sequence of the HIV gag gene to classify HIV subtypes, identify recombination sites, and detect protease inhibitor (PI) resistance-associated mutations (RAMs). The cohort included 100 people living with HIV (PLH) who had experienced antiretroviral treatment failure with reverse transcriptase/protease inhibitors. Proviral HIV-DNA was successfully sequenced in 96 out of 100 samples for gag regions, specifically matrix (p17) and capsid (p24). Moreover, from these 96 sequences, 82 (85.42%) were classified as subtype B, six (6.25%) as subtype F1, one (1.04%) as subtype C, and seven (7.29%) exhibited a mosaic pattern between subtypes B and F1 (B/F1), with breakpoints at p24 protein. Insertions and deletions of amino acid at p17 were observed in 51 samples (53.13%). The prevalence of PI RAM in the partial gag gene was observed in 78 out of 96 PLH (81.25%). Among these cases, the most common mutations were R76K (53.13%), Y79F (31.25%), and H219Q (14.58%) at non-cleavage sites, as well as V128I (10.42%) and Y132F (11.46%) at cleavage sites. While B/F1 recombination was identified in the p24, the p17 coding region showed higher diversity, where insertions, deletions, and PI RAM, were observed at high prevalence. In PLH with virological failure, the analysis of the partial gag gene could contribute to more accurate predictions in genotypic resistance to PIs. This can aid guide more effective HIV treatment strategies.


  • Detection of unreported usage of the antiretroviral drug lamivudine in two blood donors

    by Anna Nishiya, Nanci Salles, Cesar de Almeida‐Neto, Suzete Ferreira, Fátima Nogueira, Vanderson Rocha, Alfredo Mendrone‐Júnior

    Background: Unreported HIV antiretroviral (ARV) drug usage by blood donors compromises the ability to detect evidence of HIV infection in blood screening tests and represents a risk for blood transfusion safety. Our objective was to determine the frequency of undeclared ARV drug use by blood donors with altered HIV markers.Study Design and Methods: This was a retrospective cross‐sectional analysis of donations that were tested for HIV antibody (ab), antigen (ag), and RNA by chemiluminescent immunoassay and nucleic acid screening tests. Positive samples were retested and were subjected to ARV drug testing by high‐performance liquid chromatography–tandem mass spectrometry.Results: Of 345,252 blood donations, 361 (0.1%) were positive on initial testing. Samples from 296 (81.9%) of these donations were available for further analysis. The presence of HIV ab/ag and/or RNA was confirmed in 83 (28.0%) of these samples. All 296 bloods were subjected to ARV testing. The ARV drug lamivudine, at 11.3 and 6.7 ng/mL, was detected in 2 of 83 (2.4%) donations that were HIV positive. Other drugs were not detected.Conclusion: Unreported ARV usage was identified in two candidates for blood donation. More intensive efforts to educate donors about disclosure and to investigate the extent of this phenomenon in Brazil are needed.


  • Improved detection of hepatitis C virus‐positive blood donors and determination of infection status

    by Anna S. Nishiya, Cesar de Almeida‐Neto, Steven S. Witkin, Suzete C. Ferreira, Nanci A. Salles, Fátima A. H. Nogueira, Claudia Di Lorenzo Oliveira, Vanderson Rocha, Alfredo Mendrone Júnior

    Background: In low‐risk populations, variability in the sensitivity of current serological tests for Hepatitis C virus (HCV) blood donor screening may lead to the presence of false‐positive results. This contributes to the unnecessary loss of blood donor samples as well as to difficulty in accurate donor counselling. The present study determined the optimal cut‐off value of a chemiluminescent immunoassay for identification of HCV‐reactive blood donors.Study Design and Methods: In a retrospective cross‐sectional analysis of 193 973 blood donations, 578 samples that were positive for HCV antibody in a chemiluminescent immunoassay and/or RNA screening tests were identified. Blood from 379 of these positive samples was available for retesting by a second confirmatory HCV immunoassay followed by a receiver operating characteristic (ROC) curve analysis. Donors were also recalled for a new analysis.Results: Only 71 (18.7%) blood samples remained HCV‐positive upon retesting, while 233 (61.5%) now tested negative and 75 (19.8%) yielding indeterminate results. A signal to cutoff ratio ≥4.32 was determined as the best differential threshold between a positive and negative result, increasing the positive predictive value from 27.3% to 66.7%.Conclusion: Using a higher threshold for an HCV‐positive blood sample enhances the chemiluminescent immunoassay screening test´s accuracy and helps to improve donor counselling and notification processes.


  • Open Access

    Transfusion-Acquired HIV: History, Evolution of Screening Tests, and Current Challenges of Unreported Antiretroviral Drug Use in Brazil

    by Anna S. Nishiya, Suzete C. Ferreira, Nanci A. Salles, Vanderson Rocha, Alfredo Mendrone-Júnior

    Prevention of HIV acquisition by blood transfusion from its emergence to the present day is reviewed, and current challenges are delineated. The experience of Fundação Pró-Sangue/Hemocentro de São Paulo, Brazil, is highlighted in the quest for improvements in blood safety and the evolution of increasingly sensitive and specific screening tests. Concerns and establishing stringent criteria in the screening of potential blood donors are emphasized, and the current criteria for identifying and deferring candidates at high risk of acquiring sexually transmitted diseases are summarized. Future challenges relate to the identification of donors with unreported use of antiretroviral drugs for prophylaxis against possible HIV exposure or for treatment of an HIV infection whose viral expression is undetectable by current analyses. There is a need to better understand the motivation of HIV-exposed donors and to educate them about the risk of transfusion-mediated HIV transmission despite having low or undetectable viral loads. In situations in which traditional HIV RNA or antibody detection assays remain negative, more sensitive analyses are needed to identify potential donors at risk for HIV transmission.


  • Influence of unreported HIV prophylaxis on the kinetics of post‐blood donation HIV seroconversion

    by Anna S. Nishiya, Nanci A. Salles, Cesar de Almeida‐Neto, Steven S. Witkin, Suzete C. Ferreira, Fátima A. H. Nogueira, Tila Facincani, Vanderson Rocha, Alfredo Mendrone‐Jr

    Background: In 2020, of 110,000 blood donors screened for HIV exposure two individuals were identified who were viral RNA‐positive but seronegative. One of the donors, borderline negative in a pooled screening test for HIV RNA, utilized antiretroviral drugs as post‐exposure, pre‐donation prophylaxis. The kinetics of subsequent HIV seropositivity in both donors are described.Study Design and Methods: Both donors were recalled and interviewed, and blood was obtained at intervals for HIV antibodies and RNA testing.Results: One donor used antiretroviral prophylaxis for 30 days due to a relationship with an HIV‐positive partner. In follow‐up samples, seroconversion was noted at 70 days, and viral RNA was detected at 105 days, after blood donation. In contrast, the other donor seroconverted in <25 days and the appearance and titer of HIV RNA was in accordance with the typical pre‐seroconversion window.Conclusion: The use of anti‐viral prophylaxis by blood donors in the acute phase of HIV infection delays seroconversion. A 6‐month deferral in blood donation after HIV prophylaxis, as currently recommended in Brazil, would have been sufficient in this case to mitigate the risk of transfusion‐transmitted HIV. Ultimately, improvement in donor compliance with selection procedures for blood donation is needed to optimize blood safety.